SLB
45
4
AIV
51
4
DG
27
-2
PFE
21
-2
LUV
40
2
PCAR
56
7
AEP
48
5
GME
57
2
CA
16
3
SLG
66
4
LOW
53
3
MS
69
3
MU
39
5
COST
54
4
JPM
59
3
SRE
52
2
NDAQ
56
3
LMT
29
2
PSA
56
5
BAX
41
3
SLB
45
4
AIV
51
4
DG
27
-2
PFE
21
-2
LUV
40
2
PCAR
56
7
AEP
48
5
GME
57
2
CA
16
3
SLG
66
4
LOW
53
3
MS
69
3
MU
39
5
COST
54
4
JPM
59
3
SRE
52
2
NDAQ
56
3
LMT
29
2
PSA
56
5
BAX
41
3
Financhill
Back

LanzaTech Global 10K Form

Buy
55

LNZA
LanzaTech Global

Last Price:
1.78
Seasonality Move:
4.79%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LNZA News And Ratings

See the #1 stock for the next 7 days that we like better than LNZA

LNZA Financial Statistics

Sales & Book Value

Annual Sales: $62.63M
Cash Flow: $-16.44M
Price / Cash Flow: 0
Annual Sales: $0.34
Price / Book: 5.59

Profitability

EPS (TTM): -0.49000
Net Income (TTM): $-97.31M
Gross Margin: $17.65M
Return on Equity: -79.25%
Return on Assets: -39.99%

LanzaTech Global Earnings Forecast

Key LanzaTech Global Financial Ratios

  • The Gross Profit Margin over the past 4 years for LNZA is 28.18%.
  • The Selling, General & Administrative Expenses for LNZA have been equal to 80.53% of Gross Profit Margin.
  • The Research & Development expenses have been 108.80% of Revenue.
  • The Interest Expense is -0.01% of Operating Income.
  • The Net Earning history of LNZA is -214.11% of Total Revenues.
  • Per Share Earnings over the last 4 years have been positive in 0 years.

LanzaTech Global Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Commercial Services & Supplies
Sector: Industrials
Current Symbol: LNZA
Website: lanzatech.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.4
Quick Ratio: 3.89

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

LNZA Technical Analysis vs Fundamental Analysis

Buy
55
LanzaTech Global (LNZA) is a Buy

Is LanzaTech Global a Buy or a Sell?

  • LanzaTech Global stock is rated a Buy
    The current LanzaTech Global [LNZA] share price is $1.91. The Score for LNZA is 55, which is 10% above its historic median score of 50, and infers lower risk than normal.